SENS

Over the past six months, Senseonics Holdings, Inc. experienced several stock-impacting events. On September 14, 2026, a strategic partnership with Beta Bionics was announced to integrate Eversense® 365 with the iLet® Bionic Pancreas. Q2 2026 financial results, reported on August 6, 2026, showed a 120% year-over-year revenue increase to $14.5 million, with U.S. revenue up over 150%, and gross margin improved to 59%. Full-year 2026 revenue guidance was raised to $62-$66 million, though net loss widened to $36.7 million due to higher R&D and SG&A expenses. On June 1, 2026, Senseonics highlighted an analyst event and an oral presentation of Eversense 365 real-world evidence at ADA 2026. Q1 2026 revenue was $11.7 million, up 87% year-over-year, and the company raised over $100 million in equity and debt. Barclays downgraded Senseonics to a Hold rating with a $10 target price on October 6, 2026, and an activist investor took a major stake around August 16, 2026. The stock price was $9.96 per share on October 1, 2026, a 14.22% increase from October 2, 2025, but experienced recent declines of -9.49% weekly and -6.15% monthly as of October 11, 2026.